Sanjivani Paranteral Ltd Q4 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/3fouml3pdzbrmbpv6gjxvrnf.pdf

Key Takeaways


Export Operations & Geopolitical Disruption

Pritesh Jain: "the March month for this quarter was highly affected due to the geopolitical tensions on account of war between US and Iran. So, the shipping routes, availability of the containers and the logistical chain was disrupted and hence we couldn't do major shipments, which we normally do every year in the month of March."

Pune IV Fluid Facility Ramp-Up


Base Business & Product Mix

Pritesh Jain: "We don't have a long-term contract with our buyers wherein we are stuck for the price fixation. So, our price part is open depending on the international price revisions and rates."

Margins & Input Costs


Balance Sheet & Working Capital


Nutraceutical Venture & Other Updates

Ashwani Khemka: "we are under negotiation from majority state but it is yet to happen. When it will be happen we will be announcing it."

Guidance & Commitments

CommitmentSpecificsTimeline
Export revenue recoveryBroader recovery expected; disruption impact largely behindQ1 FY27 (Apr–Jun 2026)
Pune IV facility utilizationRamp from 40% → 45% → 60% → 70% across four quartersQ1–Q4 FY27
Pune IV facility annual revenue₹60–65 croreFY27
Base business annual revenue₹80–85 croreFY27
IV business breakevenBreakeven expectedFY27
Pune IV facility full-year EBITDA margin17–18%FY27
Debtor days55–60 daysComing periods
Product approvals for Pune plantChunk of 18 pipeline products expectedThis month

Key Metrics

MetricQ4 FY26
Consolidated revenue₹13.21 cr
Standalone base business revenue₹10.51 cr
Consolidated EBITDA₹2.17 cr, margin 15.74%
Standalone EBITDA₹1.66 cr, margin 14.7%
Consolidated PAT₹0.55 cr, margin 3.97%
Standalone PAT₹0.94 cr
Injectable revenue₹4.67 cr, 44.43% of standalone revenue
Tablet revenue₹5.46 cr, 51.95% of standalone revenue
Export revenue₹8.96 cr, 85.26% of standalone revenue
Domestic revenue₹1.47 cr
Core markets share76.09% of standalone revenue (Latin America, Middle East, Africa, CIS)
Pune IV facility revenue₹2.7 cr, up from ₹1.2 cr in Q3 FY26
FY27 base business target₹80–85 cr
FY27 Pune IV plant target₹60–65 cr
FY27 base business EBITDA margin target15.5% to 16.5%
FY27 IV business EBITDA margin target17% to 18% on annualized basis
Debtor days65–70 days, improved from 90 days in prior year
Middle East and Africa revenue contribution40% to 45% of topline
Pune IV facility annual capacity6 cr bottles
Pune IV facility Q3+Q4 volume0.2 cr bottles, contributing ~₹3.5 cr revenue
Pune IV facility product approvals5 approved, 18 in pipeline
Prague nutraceutical JV revenueEUR 500,000 to EUR 600,000 last year
Sanjivani stake in Prague JV45%
Import contributionLess than 1% of total turnover